Results 1 to 10 of about 15,000 (182)
Modified recombinant human erythropoietin with potentially reduced immunogenicity [PDF]
Scientific Reports, 2021 Recombinant human erythropoietin (rHuEPO) is a biopharmaceutical drug given to patients who have a low hemoglobin related to chronic kidney disease, cancer or anemia.
Thanutsorn Susantad +5 more
doaj +2 more sources
Prophylactic Erythropoietin for Neuroprotection in Very Preterm Infants: A Meta-Analysis Update
Frontiers in Pediatrics, 2021 A meta-analysis update of randomized controlled trials investigating recombinant human erythropoietin suggests improved neurodevelopmental outcome in preterm infants.
Hendrik S. Fischer +3 more
doaj +1 more source
Current Oncology, 2021 Background: The high proportion of blood transfusions before and during surgery carries unnecessary risk and results in poor prognosis in colorectal cancer patients.
Chao-Ming Hung +7 more
doaj +1 more source
Pleiotropic effects of Erythropoietin. Influence of Erythropoietin on processes of mesenchymal stem cells differentiation [PDF]
Research Results in Pharmacology, 2019 Structure and synthesis of Erythropoietin: Erythropoietin (EPO) is a glycoprotein hormone. Recombinant Erythropoietin (Epoetin): Human recombinant erythropoietin is characterised as a factor which stimulates differentiation and proliferation of ...
Ekaterina V. Zubareva +4 more
doaj +3 more sources
A lentiviral gene therapy strategy for the in vitro production of feline erythropoietin. [PDF]
PLoS ONE, 2012 Nonregenerative anemia due to chronic renal failure is a common problem in domestic cats. Unfortunately, administration of recombinant human erythropoietin often only improves anemia temporarily due to antibody development. In this in vitro study, feline
Natalia Vapniarsky +3 more
doaj +1 more source
Serum erythropoietin levels, breast cancer and breast cancer-initiating cells
Breast Cancer Research, 2019 Background Cancer is frequently associated with tumor-related anemia, and many chemotherapeutic agents impair hematopoiesis, leading to impaired quality of life for affected patients.
Kruttika Bhat +11 more
doaj +1 more source
Erythropoietin protects sensory axons against paclitaxel-induced distal degeneration
Neurobiology of Disease, 2006 Paclitaxel causes a sensory polyneuropathy with characteristic features of distal axonal degeneration. Although the exact mechanisms underlying distal axonal degeneration are unknown, paclitaxel-induced axonal degeneration has been shown to be associated
Giorgia Melli +4 more
doaj +1 more source
Asian Journal of Transfusion Science, 2013 Introduction: To study whether the administration of recombinant human erythropoietin increases the amount of autologous blood that can be collected before orthopaedic surgery.
Kumkum Sharma +4 more
doaj +1 more source
Recombinant human erythropoietin in nephrology
Biomedicine & Pharmacotherapy, 1989 rEPO therapy provides a unique opportunity to correct anemia in end-stage renal failure patients. Complete correction of the anemia, although possible, has some obvious disadvantages over a partial correction with a target hemoglobin of 10-13 g/dl or a hematocrit of 30-35%, respectively.
W, Samtleben, P, Ivanovich, H J, Gurland
openaire +2 more sources
The role of carbohydrate in recombinant human erythropoietin [PDF]
European Journal of Biochemistry, 1990 Recombinant human erythropoietin has N‐linked sugar [Tsuda et al., (1988) Biochemistry 27, 5646–5654]. Here we have demonstrated the presence of O‐linked sugar (0.85 mol/mol erythropoietin) composed of sialic acid and Galβ(1–3)GalNAc. To investigate the role of these sugars, erythropoietins deglycosylated to different extents were prepared using ...
E, Tsuda +4 more
openaire +2 more sources